G.d. Searle & Company

Other

John C Smith

Leslie D Bell

Paul G Boseley

Michael Houghton

John Robert Adair

Alan G Porter

Norman H Carey

Michael A Eaton

Arthur Britton

Michael T Doel

John A Page

David M Lilley

Modified beta interferons containing amino acid substitutions in the beta interferon amino acids 1 to 56 are described. These modified beta interferons exhibit changes in the antiviral, cell growth regulatory or immunomodulatory activities when compared with unmodified beta interferon.

Modified (1-56) beta interferons

Modified beta interferons containing amino acid substitutions in the beta interferon amino acids 80 to 113 are described. These modified beta interferons exhibit changes in the antiviral, cell growth regulatory or immunomodulatory activities when compared with unmodified beta interferon.

Modified (80-113) beta interferons

Human interferons containing novel cysteine substitutions and disulfide bonds are disclosed. The amino acid sequence of a first interferon is combined with the cysteine and/or disulfide pattern of a second interferon resulting in a molecule with hybrid properties.

Interferons with novel cysteine pattern

Modified beta interferons containing amino acid substitutions in the beta interferon amino acids 1 to 28 are described. These modified beta interferons exhibit changes in the antiviral, cell growth regulatory or immunomodulatory activities when compared with unmodified beta interferon.

Modified (1-28) beta interferons

Modified beta interferons containing amino acid substitutions in the beta interferon amino acids 115 to 145 are described. These modified beta interferons exhibit changes in the antiviral, cell growth regulatory or immunomodulatory activities when compared with unmodified beta interferon.

Modified (115-145) beta interferons

A synthetic gene characterised in that it codes for the expression of urogastrone or a sub-unit thereof is disclosed. The production thereof by the assembly and ligation of a number of nucleotide blocks is also disclosed, as are corresponding plasmid recombinants, transformed cells and the production thereof. The expression of urogastrone is further disclosed. Urogastrone is a polypeptide hormore (protein) which may be isolated in small amounts from human urine. It has an application in the treatment of ulcers and in the promotion of wound healing. The present invention provides a more viable commercial production.

Synthetic urogastrone gene, corresponding plasmid recombinants,

Disclosed is an applicator for the application of liquid to webs and methods of using it. A web-guide path is defined through the applicator and has an intermediate enlargement. One or more inlets and one or more outlets are provided at the exterior of the applicator and at the enlargement respectively, which are part of a closed passageway system for the supply of liquid to the enlargement. A slit-like passageway system affords passage of web to the enlargement. An exit passageway with one outlet affords passage of web, to which liquid has been applied, from the enlargement out of the applicator. Means are provided for changing characteristics of the exit passageway whereby selectively to influence the application of liquid to the web. By using such an applicator in which provision is made for changing the size or shape, or both, of the exit passageway, considerable control may be exercised over both the degree of impregnation of the liquid into the web and the thickness of liquid coating on the web.

Growing community of inventors

High Wycombe, United Kingdom

John C Smith